Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) plans to invest 1.4985 billion yuan to participate in the establishment of Guangya Fund Phase II.

Guangzhou Baiyunshan Pharmaceutical Holdings (600332.SH) announced that the company plans to participate in the establishment of Guangzhou Pharmaceutical Fund II Equity Investment Partnership Enterprise (Limited Partnership) with a total investment of 1.4985 billion yuan as a limited partner using its own funds, accounting for 99.90% of the total committed capital of Guangzhou Pharmaceutical Fund II (tentatively named, subject to approval by the enterprise registration authority). The fund will engage in equity investment in the biopharmaceutical field through direct or indirect means to generate investment income. The fund will mainly focus on the company's strategic planning, investing in the biopharmaceutical and health sectors through sub-fund investments, direct project investments, etc., including pharmaceuticals, medical devices, and medical services. The company will effectively control Guangzhou Pharmaceutical Fund II, which will be consolidated into the company's scope. The participation in the establishment of Guangzhou Pharmaceutical Fund II aims to seize industry development opportunities, accelerate the company's industrial layout in the biopharmaceutical and health sector, and increase the company's investment efforts in the healthcare industry. This investment will help the company discover and cultivate projects that are in line with the company's core development direction and have certain market competitiveness, enriching the company's industry structure and providing project reserves for the company's future sustainable development. It will also enhance the company's operational capabilities and accelerate its external investment pace, promoting the company's rapid transformation and upgrading in the biopharmaceutical and health industry field to achieve rapid development.